Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers
Abstract
Objective:
This study compared health care use and costs among patients with treatment-resistant versus treatment-responsive depression across Medicaid, Medicare, and commercial payers.
Methods:
A retrospective cohort study was conducted by using Truven Health Analytics’ commercial (2006–2017; N=111,544), Medicaid (2007–2017; N=24,036), and Medicare supplemental (2006–2017; N=8,889) claims databases. Participants were adults with major depressive disorder who had received one or more antidepressant treatments. Treatment resistance was defined as failure of two or more antidepressant treatments of adequate dose and duration. Annual use (hospitalizations and outpatient and emergency department [ED] visits) and costs were compared across patients by treatment-resistant status in each payer population. Incremental burden of treatment-resistant depression was estimated with regression analyses. Monthly changes in costs during 1-year follow-up were assessed to understand differential cost trends by treatment-resistant status.
Results:
In the three payer populations, patients with treatment-resistant depression incurred higher health care utilization than those with treatment-responsive depression (hospitalization, odds ratios [ORs]=1.32–1.76; ED visits, ORs=1.38–1.45; outpatient visits, incident rate ratio=1.29–1.54; p<0.001 for all). Compared with those with treatment-responsive depression, those with treatment resistance incurred higher annual costs (from $4,093 to $8,054 higher; p<0.001). Patients with treatment-resistant depression had higher costs at baseline compared with patients with treatment-responsive depression and incurred higher costs each month throughout follow-up.
Conclusions:
Treatment-resistant depression imposes a significant health care burden on insurers. Treatment-resistant depression may exist and affect health care burden before a patient is identified as having treatment-resistant depression. Findings underscore the need for effective and timely treatment of treatment-resistant depression.
HIGHLIGHTS
•
Across commercially insured, Medicare, and Medicaid populations, patients with treatment-resistant depression had substantially higher health care use and costs, compared with patients with treatment-responsive depression, in the first 12 months after antidepressant initiation.
•
For the group with treatment-resistant depression, use and costs were higher even at baseline, and the higher costs persisted for every month of the follow-up year.
•
Findings suggest that treatment-resistant depression exists even before treatment resistance is evident, which highlights the need for early identification and close monitoring of patients who are less likely to respond to treatment.
Major depressive disorder is a significant public health concern in the United States, with a lifetime prevalence estimated at 19.2% and a 1-year prevalence of 7.1% (1, 2). Treatment-resistant depression refers to major depressive disorder that fails to respond to adequate treatment. Depending on the definition, treatment-resistant depression affects an estimated 20%−30% of patients with major depressive disorder (3). Patients with treatment-resistant depression have higher symptom severity, longer episodes of depression, diminished quality of life, and an increased suicide risk, compared with patients with treatment-responsive depression (3–6). These data suggest the potential benefits that timely and effective antidepressant treatment can have for patients with major depressive disorder. However, individuals with treatment-resistant depression currently have limited proven treatment options (7, 8).
Previous research that examined the burden of treatment-resistant depression among commercially insured and Medicaid populations found significantly higher health care resource utilization and costs among patients with treatment-resistant depression, compared with patients with treatment-responsive depression and patients without major depressive disorder (5, 9–13). One study, which used 2001–2009 data and included Medicaid, Medicare, and commercially insured populations, found that treatment-resistant depression was associated with 29.3% higher health care costs (14). However, this study defined treatment-resistant depression at a higher threshold of treatment failure, which may have resulted in underestimation of total health care burden.
Given the heterogeneity in operationally defining treatment-resistant depression, it is challenging to compare between studies the extent to which patterns in treatment-resistant depression burden are analogous across payers. This study aimed to explore these intricacies by applying a standardized definition of treatment-resistant depression across patients with major depressive disorder among the following payer populations: commercial, Medicaid, and Medicare. This study assessed the incremental treatment burden of treatment-resistant depression among patients with major depressive disorder by comparing health care resource utilization and associated costs across patients with treatment-resistant depression versus patients with treatment-responsive depression covered by commercial, Medicaid, and Medicare supplemental health plans. In addition, this study sought to understand health care cost trends over time associated with health care resource utilization by treatment-resistant depression status.
Methods
Data Source
This retrospective observational study used administrative claims data from three Truven MarketScan databases (commercial, Medicare supplemental, and Medicaid databases) to capture person-specific health care utilization and associated expenditures from January 2006 (for commercial and Medicare supplemental) or January 2007 (for Medicaid) through October 2017. The commercial database includes employees and their family members in the United States covered by private health insurance provided by approximately 100 large employers. The Medicaid database includes over 44 million Medicaid enrollees from multiple states. The Medicare supplemental database includes retired beneficiaries with supplemental health care insurance covered by employers and includes records of all services paid by Medicare, private insurance, and beneficiaries as out-of-pocket costs (15). Each database contains information on eligibility, demographic characteristics, inpatient and outpatient medical claims, outpatient prescription claims, and costs associated with adjudicated claims. Institutional review board approval was not sought for this study because all data had been previously collected and deidentified.
Study Population
The study included adults ages 18 and older with a major depressive disorder diagnosis (ICD-9-CM codes 296.2x, 296.3x; ICD-10-CM codes F32.x, F33.x) who had received an antidepressant treatment anytime between April 1, 2006, and October 31, 2016. In addition, patients were required to have continuous enrollment in their benefit plans during the 6 months preindex and 12 months postindex date, where index date was defined as the date on which they received their initial antidepressant treatment. Patients were excluded if they had a diagnosis of schizophrenia, bipolar disorder, dementia, or other psychosis. (A CONSORT diagram of sample composition is available in an online supplement to this article.)
Patients were further stratified into those with treatment-resistant and treatment-responsive depression based on their treatment patterns. Treatment-resistant depression was defined as failure of at least two antidepressant treatment courses of adequate dose and duration within a depressive episode among patients with a major depressive disorder. Adequate dose was defined as the minimum starting dose recommended by the American Psychiatric Association (16). Adequate duration was defined as at least 6 weeks of continuous therapy with no gaps in medication possession longer than 14 days. Failure of a treatment course was defined as an antidepressant molecule switch within or outside of the treatment class within 90 days after the end of the previous treatment, the addition of a new antidepressant, or the initiation of an augmentation therapy. The date of initiation of the third antidepressant or augmentation medication following the failure of two treatments at adequate dose and duration was used as the date of treatment-resistant depression diagnosis. Patients with treatment-responsive depression were identified from the subset of patients who were not identified as having treatment-resistant depression. Because of the large size of the treatment-responsive populations, 15% of these patients were randomly selected for inclusion in this study to mitigate the risk of overpowering the study (see online supplement for a table listing inclusion and exclusion criteria).
Outcome Measures
Outcomes included all-cause and mental health–related health care utilization (i.e., outpatient visits, hospitalizations, and emergency department [ED] visits) and health care costs over the 12-month postindex follow-up period. Health care costs were adjusted to 2018 dollar values by using the medical care component from the Consumer Price Index (17).
Only a few patients across the three payer populations reported having any hospitalizations or ED visits at any point during the follow-up period. Hence, these outcomes were collapsed to binary variables representing any hospitalization or ED visit versus no hospitalization or ED visit, respectively.
We captured all health care utilization and costs incurred during the 12-month postindex follow-up period to create all-cause outcome measures. Mental health–related health care utilization and cost measures included medical and pharmacy claims with ICD-9-CM codes 290–319 or ICD-10-CM codes F01–F99.
Analytic Approach
Descriptive analyses summarized patient demographic characteristics and baseline clinical characteristics (measured during the 6-month preindex period) by treatment-resistant depression status. Differences in baseline characteristics across patients with treatment-resistant and treatment-responsive depression were assessed by a regression of each characteristic, with treatment-resistant depression as the dependent variable. Separate regression analyses were carried out for each outcome of interest for each separate payer population (commercial, Medicare, and Medicaid). Logistic regressions were performed to model the association between treatment-resistant depression status and the dichotomous outcome measures (i.e., hospitalizations and ED visits). Negative binomial regressions were performed to determine the association between treatment-resistant depression status and outpatient visits. For total costs over the follow-up period, linear regression models were used to assess the relationship with treatment-resistant depression status.
All regression analyses were adjusted for the following relevant covariates: age, gender, insurance plan type, baseline Charlson Comorbidity Index (CCI) score, and baseline all-cause health care costs. Information on race-ethnicity was available only for the Medicaid sample, whereas information on region was available only for the commercial and Medicare data sets. Hence, these variables were included in the analysis of the corresponding payer populations.
In addition, the study examined the time trend of health care costs, or the monthly changes in average all-cause and mental health–related health care costs during the 12-month follow-up period to understand the differential trends in costs associated with resource utilization by treatment-resistant depression status.
Results
Demographic and Baseline Clinical Characteristics
Sample sizes for patients with treatment-resistant depression were as follows: commercial, N=27,595; Medicaid, N=5,556; and Medicare, N=1,856. Sample sizes for patients with treatment-responsive depression were as follows: commercial, N=83,949; Medicaid, N=18,480; and Medicare, N=7,033. Tables 1–3 summarize demographic and baseline clinical characteristics, stratified by treatment-resistant depression status, for each of the three samples.
| Treatment-resistant depression | |||||||
|---|---|---|---|---|---|---|---|
| No (N=83,949) | Yes (N=27,595) | ||||||
| Characteristic | N | % | N | % | ORa | 95% CI | |
| Age | |||||||
| 18–24 | 12,927 | 15.4 | 4,081 | 14.8 | .95 | .92–.99 | |
| 25–34 | 17,893 | 21.3 | 5,611 | 20.3 | .94 | .91–.97 | |
| 35–49 | 28,864 | 34.4 | 9,648 | 35.0 | 1.03 | 1.00–1.06 | |
| 50–64 | 24,265 | 28.9 | 8,255 | 29.9 | 1.05 | 1.02–1.08 | |
| Gender | |||||||
| Female | 56,625 | 67.5 | 18,346 | 66.5 | .96 | .93–.99 | |
| Region | |||||||
| Northeast | 14,563 | 17.4 | 4,669 | 16.9 | .97 | .94–1.01 | |
| North Central | 18,969 | 22.6 | 6,579 | 23.8 | 1.07 | 1.04–1.11 | |
| South | 31,519 | 37.6 | 10,602 | 38.4 | 1.04 | 1.01–1.07 | |
| West | 18,228 | 21.7 | 5,508 | 20.0 | .90 | .80–.93 | |
| Unknown | 670 | .8 | 237 | .9 | 1.08 | 1.04–1.11 | |
| Health care plan type | |||||||
| Preferred provider organization | 47,101 | 57.9 | 15,998 | 60.0 | 1.09 | 1.06–1.12 | |
| Point of service (POS) or POS with capitation | 8,432 | 10.4 | 2,748 | 10.3 | .99 | .95–1.04 | |
| Health maintenance organization | 15,141 | 18.6 | 4,335 | 16.3 | .85 | .82–.88 | |
| Other | 10,685 | 13.1 | 3,589 | 13.5 | 1.03 | .99–1.07 | |
| Charlson Comorbidity Indexb | |||||||
| 0 | 73,986 | 88.1 | 23,609 | 85.6 | .80 | .77–.83 | |
| 1 | 5,728 | 6.8 | 2,243 | 8.1 | 1.21 | 1.15–1.27 | |
| ≥2 | 4,235 | 5.0 | 1,743 | 6.3 | 1.27 | 1.20–1.34 | |
| Relevant mental disorders | |||||||
| Anxiety | 12,647 | 15.1 | 4,696 | 17.0 | 1.16 | 1.11–1.20 | |
| Otherc | 21,423 | 25.5 | 8,070 | 29.2 | 1.21 | 1.17–1.24 | |
| M | SD | M | SD | p | |||
| Baseline total health care costs ($) | |||||||
| All cause | 6,491.85 | 24,719.03 | 9,111.29 | 30,989.35 | <.001 | ||
| Mental health related | 1,100.86 | 7,865.50 | 1,507.58 | 9,354.75 | <.001 | ||
a
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) are from separate logistic regressions for each patient characteristic, with treatment-responsive depression as the reference group.
b
Measure of the number of comorbid conditions (0, 1, or ≥2).
c
A mental disorder other than major depressive disorder, schizophrenia, bipolar disorder, dementia, or anxiety. Patients were excluded from the sample if they had a diagnosis of schizophrenia, bipolar disorder, dementia, or other psychosis.
| Treatment-resistant depression | ||||||
|---|---|---|---|---|---|---|
| No (N=18,480) | Yes (N=5,556) | |||||
| Characteristic | N | % | N | % | ORa | 95% CI |
| Age | ||||||
| 18–24 | 3,121 | 16.9 | 324 | 5.8 | .30 | .27–.34 |
| 25–34 | 5,542 | 30.0 | 1,312 | 23.6 | .72 | .67–.77 |
| 35–49 | 5,215 | 28.2 | 2,050 | 36.9 | 1.49 | 1.40–1.58 |
| 50–64 | 4,602 | 24.9 | 1,870 | 33.7 | 1.53 | 1.43–1.63 |
| Gender | ||||||
| Female | 14,063 | 76.1 | 4,194 | 75.5 | .97 | .90–1.04 |
| Race | ||||||
| White | 12,182 | 65.9 | 4,309 | 77.6 | 1.79 | 1.67–1.92 |
| Health care plan type | ||||||
| Comprehensive | 7,313 | 39.6 | 2,871 | 51.7 | 1.63 | 1.54–1.73 |
| Health maintenance organization | 10,532 | 57.0 | 2,459 | 44.3 | .60 | .56–.64 |
| Other | 634 | 3.4 | 226 | 4.1 | 1.19 | 1.02–1.39 |
| Charlson Comorbidity Indexb | ||||||
| 0 | 13,500 | 73.1 | 3,727 | 67.1 | .75 | .70–.80 |
| 1 | 2,837 | 15.4 | 1,027 | 18.5 | 1.25 | 1.16–1.23 |
| ≥2 | 2,143 | 11.6 | 802 | 14.4 | 1.29 | 1.18–1.40 |
| Relevant mental disorders | ||||||
| Anxiety | 4,174 | 22.6 | 1,391 | 25.0 | 1.14 | 1.07–1.23 |
| Otherc | 8,728 | 47.2 | 2,755 | 49.6 | 1.10 | 1.04–1.17 |
| M | SD | M | SD | p | ||
| Baseline total health care costs ($) | ||||||
| All cause | 5,631.69 | 29,984.23 | 6,736.44 | 28,431.21 | .015 | |
| Mental health related | 2,009.95 | 21,520.86 | 2,279.44 | 11,778.57 | .371 | |
a
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) are from separate logistic regressions for each patient characteristic, with treatment-responsive depression as the reference group.
b
Measure of the number of comorbid conditions (0, 1, or ≥2).
c
A mental disorder other than major depressive disorder, schizophrenia, bipolar disorder, dementia, or anxiety. Patients were excluded from the sample if they had a diagnosis of schizophrenia, bipolar disorder, dementia, or other psychosis.
Health Care Utilization
Across the three payer populations, we found significantly greater health care utilization in all three outcomes (i.e., hospitalizations, ED visits, and outpatient visits) for patients with treatment-resistant depression, compared with those with treatment-responsive depression (see figure in online supplement ). Among patients with treatment-resistant depression, the odds of all-cause hospitalization were significantly greater, compared with patients with treatment-responsive depression (odds ratios [ORs]=1.32–1.76, p<0.001), as were the odds of mental health-related hospitalization (ORs=1.46–2.22, p<0.001). Among patients with treatment-resistant depression, the odds of all-cause ED visits were also significantly greater (ORs=1.38–1.45, p<0.001), as were the odds of mental health-related ED visits (ORs=1.49–2.06, p<0.001). The likelihood of all-cause outpatient visits was also higher among those with treatment-resistant depression (incident rate ratios [IRRs]=1.29–1.54 , p<0.001), as was the likelihood of mental health–related outpatient visits (IRRs=1.51 to 1.92 , p<0.001).
Health Care Costs
The findings for health care costs were consistent across all payer populations: patients with treatment-resistant depression incurred higher all-cause and mental health–related annual costs, compared with patients with treatment-responsive depression (Table 4). The incremental all-cause cost burden for patients with treatment-resistant depression, compared with their counterparts with treatment-responsive depression, ranged from $4,093 among Medicaid beneficiaries to $8,054 among Medicare beneficiaries, with an incremental cost burden of $6,742 among commercially insured patients (p<0.001 for all).
| Treatment-resistant depression | ||||||
|---|---|---|---|---|---|---|
| No (N=7,033) | Yes (N=1,856) | |||||
| Characteristic | N | % | N | % | ORa | 95% CI |
| Age | ||||||
| 65–70 | 2,669 | 38.0 | 872 | 47.0 | 1.45 | 1.31–1.61 |
| 71–75 | 1,528 | 21.7 | 427 | 23.0 | 1.08 | .95–1.22 |
| ≥76 | 2,836 | 40.3 | 557 | 30.0 | .63 | .56–.71 |
| Gender | ||||||
| Female | 4,482 | 63.7 | 1,140 | 61.4 | .91 | .82–1.01 |
| Region | ||||||
| Northeast | 1,249 | 17.8 | 310 | 16.7 | .93 | .81–1.06 |
| North Central | 2,386 | 33.9 | 602 | 32.4 | .94 | .84–1.04 |
| South | 1,834 | 26.1 | 571 | 30.8 | 1.26 | 1.13–1.41 |
| West | 1,554 | 22.1 | 369 | 19.9 | .87 | .77–.99 |
| Health care plan type | ||||||
| Preferred provider organization | 2,678 | 38.3 | 714 | 38.7 | 1.02 | .92–1.13 |
| Comprehensive | 2,904 | 41.6 | 779 | 42.3 | 1.03 | .93–1.14 |
| Health maintenance organization | 1,097 | 15.7 | 256 | 13.9 | .87 | .92–1.13 |
| Other | 311 | 4.5 | 95 | 5.2 | 1.17 | .75–1.00 |
| Charlson Comorbidity Indexb | ||||||
| 0 | 4,292 | 61.0 | 1,080 | 58.2 | .89 | .80–.99 |
| 1 | 1,080 | 15.4 | 303 | 16.3 | 1.08 | .94–1.24 |
| ≥2 | 1,661 | 23.6 | 473 | 25.5 | 1.11 | .98–1.24 |
| Relevant mental disorders | ||||||
| Anxiety | 661 | 9.4 | 227 | 12.2 | 1.34 | 31.14–1.58 |
| Otherc | 1,240 | 17.6 | 378 | 20.4 | 1.19 | 1.05–1.36 |
| M | SD | M | SD | p | ||
| Baseline total health care costs ($) | ||||||
| All cause | 16,726.87 | 47,802.85 | 17,362.93 | 46,721.89 | .609 | |
| Mental health related | 1,382.08 | 9,144.70 | 2,622.60 | 34,351.02 | .007 | |
a
Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) intervals are from separate logistic regressions for each patient characteristic, with treatment-responsive depression as the reference group.
b
Measure of the number of comorbid conditions (0, 1, or ≥2).
c
A mental disorder other than major depressive disorder, schizophrenia, bipolar disorder, dementia, or anxiety. Patients were excluded from the sample if they had a diagnosis of schizophrenia, bipolar disorder, dementia, or other psychosis.
A similar trend of higher annual costs among patients with treatment-resistant depression, compared with their counterparts with treatment-responsive depression, was also observed in mental health–related costs. Medicaid beneficiaries with treatment-resistant depression had the smallest incremental cost burden compared with patients with treatment-responsive depression ($2,123), followed by Medicare ($3,316) and commercially insured ($3,428) patients (p<0.001 for all).
Time Trend Analysis
In Figure 1, average total monthly all-cause and mental health–related costs in the 12-month follow-up period are shown, by treatment-resistant depression status for each payer population. Across the payer populations, patients with treatment-resistant depression started with higher costs, compared with patients with treatment-responsive depression, and continued to incur higher costs for each month throughout the follow-up period. The decline in costs over time, when present, tended to be greater for patients with treatment-responsive depression, compared with patients with treatment-resistant depression. For example, for all-cause monthly costs in month 1 versus month 12 across the three payer populations, costs for patients with treatment-resistant depression changed by +1% to –13%, compared with a decrease in costs of –21% to –32% for the patients with treatment-responsive depression. For mental health–related costs, the change from month 1 to month 12 was 0% to –37% for patients with treatment-resistant depression, compared with a decrease of –33% to –61% for patients with treatment-responsive depression.
FIGURE 1. Health care costs among patients with treatment-resistant and treatment-responsive depression in the 12 months after antidepressant medication initiation, by payera
aCosts are average monthly costs, unadjusted for covariates.
Discussion
The findings of this study indicate that across all three payer populations examined, patients with treatment-resistant depression had significantly higher health care resource utilization and costs, compared with patients with treatment-responsive depression during the first 12 months after antidepressant treatment initiation. The incremental health care utilization burden of treatment-resistant depression was most pronounced among commercially insured patients, except for ED visits. Across the three payer populations, the incremental odds of having a mental health–related ED visit were highest among Medicare patients with treatment-resistant depression, compared with their counterparts with treatment-responsive depression. Across the three payer populations, the incremental all-cause cost burden was greatest among Medicare patients, whereas the mental health–related cost burden was most pronounced among commercially insured patients.
Our findings are consistent with past studies of the burden of treatment-resistant depression that examined commercially insured and Medicaid populations and found higher health care utilization among patients with treatment-resistant depression, compared with patients with treatment-responsive major depressive disorder (12, 13). In addition, results for health care cost burden from the study reported here are in line with prior research, which estimated that commercially insured patients with treatment-resistant depression incur greater annual health care costs, compared with patients with treatment-responsive depression (10, 12). Further research is needed to quantify the incremental burden of treatment-resistant depression on health care utilization and costs, exclusive of mental health–related care.
This study adds to the growing body of research examining treatment-resistant depression burden by including a diverse sample of U.S. adults, including elderly Medicare recipients, who, to our knowledge, have not been separately evaluated before. We found that the incremental health care utilization and cost burden associated with treatment-resistant depression in the Medicare population was similar to or greater than in the Medicaid and commercially insured populations. This is the first comprehensive study of health care burden incurred by patients with treatment-resistant depression in all adult age groups (i.e., ages 18 and older). Thus these findings may inform future economic modeling work in a wider range of populations with major depressive disorder and treatment-resistant depression. Furthermore, our comparison of burden among patients with treatment-resistant depression and randomly selected patients with treatment-responsive depression involved a more representative comparison group, because the comparison was not limited only to patients with treatment-responsive depression who were very similar to patients with treatment-resistant depression, as has been the case in past studies that used matched controls; rather the comparison in our study was made against typical patients with treatment-responsive depression (5, 9, 12).
Across the three payer populations, we observed that among patients with treatment-resistant depression there was a trend toward higher baseline utilization and costs, compared with patients with treatment-responsive depression. In other words, patients with treatment-resistant and treatment-responsive depression exhibited differential resource use, even before the designation of treatment-resistant depression status. Moreover, the time trend analysis showed that higher health care costs incurred by patients with treatment-resistant depression in this study were observed right from the beginning of the follow-up period, before treatment-resistant depression was identified in most patients. One possible explanation for this trend is that patients with treatment-resistant depression may have higher baseline depression severity and comorbidity burden, as observed in the STAR*D trial, and so incur a higher cost burden from the start of treatment (18, 19). Patients with treatment-resistant depression in our study showed greater comorbidity burden, and although depression severity status was missing for most patients, we observed higher severity on the basis of depression severity–related ICD codes among patients with treatment-resistant depression, compared with patients with treatment-responsive depression (see table in online supplement ). Of note, the time trend analysis showed a high cost burden among patients with treatment-resistant depression at the time of first antidepressant treatment, which remained high throughout the follow-up period and which aligns with the expected severity course of patients with treatment-resistant depression. All groups except Medicaid patients with treatment-resistant depression experienced a decline in costs after the first month postindex. This decline was greater for patients with treatment-responsive depression, suggesting that these patients incurred decreased costs as they improved with antidepressant therapy. Collectively, these findings suggest that treatment-resistant depression is a health state that exists before a patient is identified as having treatment-resistant depression on the basis of inadequate response to treatment, and thus the findings underscore the need for early identification of treatment-resistant depression—ideally based on clinical criteria rather than treatment failures—to ensure close monitoring. Future work is needed to evaluate this relationship, because symptom severity data were missing for most patients in this analysis, and treatment-resistant depression status was inferred on the basis of pharmacy claims data.
Differences in incremental utilization and cost between patients with and without treatment-resistant depression were larger among commercial and Medicare populations, compared with the Medicaid population, possibly because of differences in patient characteristics and in plan benefit design. For example, the Medicare population represented only patients ages ≥65, and a higher proportion had a CCI score ≥2, compared with the Medicaid and commercial populations—indicating a greater number of comorbid conditions. Thus it is likely that Medicare beneficiaries had more physical illness at baseline, which led to higher utilization and subsequently higher average costs, compared with the Medicaid and commercially insured populations (see table in online supplement ).
On the other hand, the Medicaid population represents low-income patients, who often have a higher prevalence of mental illness (20). In this study, a larger proportion of Medicaid patients with and without treatment-resistant depression, compared with Medicare and commercial patients, had anxiety or other mental and behavioral health disorders. In addition, Medicaid patients both with and without treatment-resistant depression in this study had higher baseline mental health–related health care resource utilization, compared with the Medicare and commercially insured populations. However, several states have Medicaid behavioral health carve-outs, and more than 40% of Medicaid patients in this study also had health maintenance organization plans, which tend to be more restrictive than other health plans (21). Potentially, the Medicaid population in this study had a greater burden of psychiatric illness, even among those without treatment-resistant depression, compared with the Medicare and commercially insured populations, and less generous insurance benefits would have limited even higher levels of resource use above this elevated baseline. If so, that would have led to a smaller incremental burden of treatment-resistant depression in the Medicaid population, similar to the results observed in this study. However, without more nuanced data and direct comparisons, we cannot be certain of the reasons behind such differences in magnitudes of burden.
The study had some limitations. It used administrative claims data, which lacked detailed sociodemographic, behavioral, and relevant clinical characteristics, such as socioeconomic status, presence or absence of support systems, alcohol or illicit drug use, and severity of depression at baseline. If any of these missing data were strong confounders for the assessment of treatment-resistant depression status and the health care utilization and cost outcomes, the findings of this study may be biased. We included CCI score and baseline all-cause annual health care cost in the regression models as proxy measures of disease severity and health status. However, some residual bias may still exist. We were further limited by a lack of information pertaining to medication compliance for each treatment prescribed. Treatment failure was defined on the basis of the patterns of filled prescriptions as treatment discontinuation or change in or augmentation of the current treatment with another line of therapy. However, clinical information about why a patient switched therapies or discontinued use of a specific line of treatment was not available through the claims data. Finally, our data were limited to Medicare beneficiaries who received supplemental insurance through former employers, and thus these results may not be representative of the general Medicare population.
Conclusions
This comprehensive analysis, which used consistent methodology across commercially insured, Medicare, and Medicaid populations, has provided evidence that patients with treatment-resistant depression have substantially higher health care utilization and cost burden, compared with patients with treatment-responsive depression. Furthermore, a time trend analysis showed that the higher costs were incurred after initiation of antidepressant therapy but before the diagnosis of treatment-resistant depression, suggesting that the heavier economic burden is present even before treatment-resistant depression is identified. These findings highlight the need for early identification and close monitoring of patients with depression who are less likely to respond to treatment. To our knowledge, this is the first study to examine cost trends over time after antidepressant treatment initiation among patients with and without treatment-resistant depression across Medicare, Medicaid, and commercial payers. Results underscore the potential clinical and economic value of innovative, effective treatments that meet the needs of patient populations with major depressive disorder.
| Incremental annual costs | ||
|---|---|---|
| Cost and payerb | $ | 95% CI |
| All cause | ||
| Commercial | 6,742.29* | 6,218.43–7,266.16 |
| Medicaid | 4,093.37* | 3,082.22–5,104.53 |
| Medicare | 8,054.41* | 5,468.98–10,639.84 |
| Mental health related | ||
| Commercial | 3,428.10* | 3,244.83–3,611.37 |
| Medicaid | 2,122.87* | 1,650.79–2,594.95 |
| Medicare | 3,316.14* | 2,682.68–3,949.59 |
a
Linear regression models were used to assess the relationship between health care costs and treatment-resistant depression status, with treatment-responsive depression as the reference group.
b
Commercially insured and Medicare patient outcomes were adjusted for the following covariates: age, gender, region, plan type, Charlson Comorbidity Index, and baseline health care cost. Medicaid patient outcomes were adjusted for the following covariates: age, gender, race, plan type, Charlson Comorbidity Index, and baseline health care cost.
*
p<.001.
Supplementary Material
File (appi.ps.201900398.ds001.pdf)
- View/Download
- 425.45 KB
References
1.
Bromet E, Andrade LH, Hwang I, et al: Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011; 9:90
2.
Major Depression. Bethesda, MD, National Institute of Mental Health, 2019. https://www.nimh.nih.gov/health/statistics/major-depression.shtml
3.
Fekadu A, Wooderson SC, Markopoulo K, et al: What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord 2009; 116:4–11
4.
Gaynes B, Asher G, Gartlehner G, et al: Definition of Treatment-Resistant Depression in the Medicare Population. Technology Assessment Program–Technical Assessment. Rockville, MD, Agency for Healthcare Research and Quality, 2018
5.
Ivanova JI, Birnbaum HG, Kidolezi Y, et al: Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin 2010; 26:2475–2484
6.
Mrazek DA, Hornberger JC, Altar CA, et al: A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv 2014; 65:977–987
7.
FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression Available Only at a Certified Doctor’s Office or Clinic. Rockville, MD, US Food and Drug Administration, March 5, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
8.
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression. Indianapolis, Eli Lilly and Co, 2009. https://investor.lilly.com/news-releases/news-release-details/fda-approves-symbyaxr-first-medication-treatment-resistant
9.
Gibson TB, Jing Y, Smith Carls G, et al: Cost burden of treatment resistance in patients with depression. Am J Manag Care 2010; 16:370–377
10.
Greenberg P, Corey-Lisle PK, Birnbaum H, et al: Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004; 22:363–373
11.
Kubitz N, Mehra M, Potluri RC, et al: Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS One 2013; 8:e76882
12.
Amos TB, Tandon N, Lefebvre P, et al: Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J Clin Psychiatry 2018; 79:17m11725
13.
Olfson M, Amos TB, Benson C, et al: Prospective service use and health care costs of Medicaid beneficiaries with treatment-resistant depression. J Manag Care Spec Pharm 2018; 24:226–236
14.
Olchanski N, McInnis Myers M, Halseth M, et al: The economic burden of treatment-resistant depression. Clin Ther 2013; 35:512–522
15.
Hansen L: The Truven Health MarketScan Databases for Life Sciences Researchers. Ann Arbor, MI, IBM Watson Health, 2017
16.
Gelenberg A, Freeman M, Markowitz J, et al: Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Arlington, VA, American Psychiatric Association, 2010
17.
Consumer Price Index. Washington, DC, US Bureau of Labor Statistics, 2019. https://www.bls.gov/cpi/home.htm
18.
Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917
19.
Trevino K, McClintock SM, McDonald Fischer N, et al: Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry 2014; 26:222–232
20.
Results From the 2015 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD, Center for Behavioral Health Statistics and Quality, 2016
21.
Kirby JB, Machlin SR, Cohen JW: Has the increase in HMO enrollment within the Medicaid population changed the pattern of health service use and expenditures? Med Care 2003; 41(suppl):III24–III34
Information & Authors
Information
Published In
History
Received: 5 August 2019
Revision received: 20 December 2019
Accepted: 10 January 2020
Published online: 2 April 2020
Published in print: June 01, 2020
Keywords
Authors
Competing Interests
At the time this study was conducted, Dr. Shrestha and Dr. Goutam were employees of Precision Health Economics, where Dr. Jena serves as a consultant, which received research funding from Janssen Scientific Affairs. Dr. Jena has received consulting fees unrelated to this work from Amgen, Analysis Group, AstraZeneca, Biogen, Bristol Myers, Celgene, Eli Lilly, Novartis, Pfizer, Sanofi Aventis, Squibb, Tesaro, and Vertex Pharmaceuticals. Ms. Joshi and Dr. Heerlein own stock in Johnson & Johnson. The other authors report no financial relationships with commercial interests.
Funding Information
This study was funded by Janssen Scientific Affairs, LLC.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).